• Edward Topp, Rebecca Irwin, Tim McAllister, Martin Lessard, Jussi J Joensuu, Igor Kolotilin, Udo Conrad, Eva Stöger, Tsafrir Mor, Heribert Warzecha, J Chris Hall, Michael D McLean, Eric Cox, Bert Devriendt, Andrew Potter, Ann Depicker, Vikram Virdi, Larry Holbrook, Ketan Doshi, Marike Dussault, Robert Friendship, Oksana Yarosh, Han Sang Yoo, Jacqueline MacDonald, and Rima Menassa.
• Agriculture and Agri-Food Canada, London Research and Development Centre, 1391 Sandford St, London, ON N5V 4T3, Canada.
• Biotechnol. Adv. 2016 Sep 1; 34 (5): 597-604.

AbstractThe excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.Crown Copyright © 2016. Published by Elsevier Inc. All rights reserved.

18 keywords...

hide…